GlaxoSmithKline has said that its MUSCA study shows Nucala (mepolizumab) significantly improves quality of life and lung function in severe asthma patients with an eosinophilic phenotype.
The Company added the data demonstrated that “severe asthma patients, whose disease is driven by eosinophilic inflammation, treated with first-in-class biologic Nucala (mepolizumab) added-on to standard of care, achieved clinically and statistically significant improvements in their health-related quality of life and lung function, when compared to patients treated with placebo and standard of care.”
These results are from the phase IIIb MUSCA study (NCT02281318, 200862), which the Company confirmed successfully met all its primary and secondary endpoints.
At 3:04pm: (LON:GSK) GlaxoSmithKline PLC share price was -3.25p at 1684.75p
Story provided by StockMarketWire.com